Please login to the form below

Not currently logged in
Email:
Password:

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

J&J says real-world data finds no amputation risk for Invokana

J&J says real-world data finds no amputation risk for Invokana

Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) has also continued to gather pace with the company reporting sales rose 29% to just over $1bn last year.

Latest news

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics